It is not clear why Novo Nordisk had so many misgivings about maintaining this very important patent, as the 2019 maintenance fee was only CAD 450
Related Articles READERS' COMMENTS [6] Please note, only GPs are permitted to add comments to articles While the governments proposal to offer weight-loss injections to unemployed people could improve health and employability for some individuals, we also need to consider concerns about individual responsibility, stigma, cost-effectiveness, and potential drug side effects
Zepbound is exclusively for chronic weight management
It enhances the production of growth factors that aid in tissue regeneration, reduces inflammation, and protects against the harmful effects of oxidative stress
PT-141 is typically administered as a subcutaneous injection, with effects that can last up to 72 hours